103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB5405

 

Introduced 2/9/2024, by Rep. Marcus C. Evans, Jr.

 

SYNOPSIS AS INTRODUCED:
 
20 ILCS 2310/2310-730 new

    Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Sets forth requirements for any State entity or hospital that receives funding from the National Institutes of Health to conduct clinical trials of drugs or medical devices. Provides that the Department of Public Health, in consultation with relevant research organizations, shall analyze and provide recommendations on: (i) the demographic groups and populations that are currently represented and underrepresented in clinical trials in the State, including representation of groups based on their geographic location; (ii) the barriers that prevent persons who are members of underrepresented demographic groups from participating in clinical trials in the State, including barriers related to transportation; and (iii) approaches for how clinical trials can successfully partner with others to provide outreach to underrepresented communities. Provides that the Department shall report to the General Assembly on the results of the study by July 1, 2025. Sets forth definitions of underrepresented community and underrepresented demographic group. Provides that the Department shall review guidance published by the United States Food and Drug Administration and use existing infrastructure to encourage participation in clinical trials of drugs and medical devices by persons who are members of underrepresented demographic groups. Authorizes the Department to apply for any grants related to the encouragement of underrepresented demographic groups related to the United Food and Drug Administration's guidance.


LRB103 37925 CES 68057 b

 

 

A BILL FOR

 

HB5405LRB103 37925 CES 68057 b

1    AN ACT concerning State government.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Department of Public Health Powers and
5Duties Law of the Civil Administrative Code of Illinois is
6amended by adding Section 2310-730 as follows:
 
7    (20 ILCS 2310/2310-730 new)
8    Sec. 2310-730. Diversity in clinical trials.
9    (a) As used in this Section, "underrepresented community"
10or "underrepresented demographic group" means a community or
11demographic group that is more likely to be historically
12marginalized and less likely to be included in research and
13clinical trials represented by race, sex, sexual orientation,
14socioeconomic status, age, and geographic location.
15    (b) The Department of Public Health shall adopt rules
16requiring any State entity or hospital that receives funding
17from the National Institutes of Health for the purpose of
18conducting clinical trials of drugs or medical devices to:
19        (1) adopt a policy that will result in the
20    identification and recruitment of persons who are members
21    of underrepresented demographic groups to participate in
22    the clinical trials and that:
23            (A) includes a requirement for investigators who

 

 

HB5405- 2 -LRB103 37925 CES 68057 b

1        are conducting the clinical trials to collaborate with
2        community-based organizations; and
3            (B) uses methods recognized by the United States
4        Food and Drug Administration to identify and recruit
5        those persons to participate in the clinical trials;
6        (2) provide information to trial participants in
7    languages other than English;
8        (3) provide translation services or bilingual staff
9    for trial screening;
10        (4) provide culturally specific recruitment materials
11    alongside general enrollment materials; and
12        (5) provide electronic consent options when not
13    prohibited by the granting entity or federal regulations.
14    (c) The Department, in consultation with academic
15organizations, community-based organizations, and other
16relevant research organizations, shall analyze and provide
17recommendations on the following:
18        (1) the demographic groups and populations that are
19    currently represented and underrepresented in clinical
20    trials in Illinois, including representation of groups
21    based on their geographic location;
22        (2) the barriers that prevent persons who are members
23    of underrepresented demographic groups from participating
24    in clinical trials in Illinois, including barriers related
25    to transportation; and
26        (3) approaches for how clinical trials can

 

 

HB5405- 3 -LRB103 37925 CES 68057 b

1    successfully partner with community-based organizations
2    and others to provide outreach to underrepresented
3    communities.
4    By July 1, 2025, the Department shall report to the
5General Assembly the results of the analysis required under
6this subsection and any recommendations to increase diversity
7and reduce barriers for participants in clinical trials.
8    (d) The Department shall review the most recent guidance
9on race and ethnicity data collection in clinical trials
10published by the United States Food and Drug Administration
11and establish, using existing infrastructure and tools, a
12program to encourage participation in clinical trials of drugs
13and medical devices by persons who are members of demographic
14groups that are underrepresented in such clinical trials. The
15program must include, without limitation:
16        (1) collaboration with medical facilities, health
17    authorities and other local governmental entities,
18    nonprofit organizations, and scientific investigators and
19    institutions that are performing research relating to
20    drugs or medical devices to assist those investigators and
21    institutions in identifying and recruiting persons who are
22    members of underrepresented demographic groups to
23    participate in clinical trials; and
24        (2) the establishment and maintenance of an Internet
25    website that:
26            (A) provides information concerning methods

 

 

HB5405- 4 -LRB103 37925 CES 68057 b

1        recognized by the United States Food and Drug
2        Administration for identifying and recruiting persons
3        who are members of underrepresented demographic groups
4        to participate in clinical trials; and
5            (B) contains links to Internet websites maintained
6        by medical facilities, health authorities and other
7        local governmental entities, nonprofit organizations,
8        and scientific investigators and institutions that are
9        performing research relating to drugs or medical
10        devices in this State.
11    The Department may apply for grants from any source,
12including, without limitation, the Federal Government, to fund
13the requirements of this Section.